Cessation Therapeutics, Inc.

About Cessation Therapeutics, Inc.

Cessation Therapeutics is dedicated to saving lives by developing a novel antibody therapy to prevent overdoses related to fentanyl and its analogs. Their mission focuses on combating the fentanyl crisis in the United States, where it is the leading cause of death for Americans aged 18 to 45.

Products & Services

Anti-Fentanyl Monoclonal Antibody Treatment:A treatment designed to provide ongoing and durable protection from fentanyl overdose by capturing fentanyl in the bloodstream and blocking its entry to the brain, thereby preventing life-threatening effects like respiratory depression.

Specialties

Antibody Therapy Fentanyl Overdose Prevention Monoclonal Antibody Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 14800000 MR: - FA: $14.8 million FAN: 14800000	D: 2023-10-18 FD: 2023-10-18	1 investors

Grant Latest

2023-10-18

$14.8M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrew C. Barrett

President and Chief Scientific Officer

P

Paul Bremer, Ph.D.

Vice President, R&D and CMC

J

John Katsilometes

Interim Controller

J

Joshua Sills

Operations

M

Mark E. Pearson

Co-Founder & Board Member

J

John D. Harkey, Jr.

Co-Founder & Board Member

View 6 more team members with Pro

Unlock Full Team Directory

Recent News